Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Controlled Clinical Trial Evaluating Methotrexate or Leflunomide + Targeted Therapy Versus Methotrexate or Leflunomide + Sulfasalazine + Hydroxychloroquine in Patients With Rheumatoid Arthritis and Insufficient Response to Methotrexate or Leflunomide

NCT02714634 is registered in ClinicalTrials.gov with University Hospital, Strasbourg, France as lead sponsor.

NCT NCT02714634
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02714634 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Controlled Clinical Trial Evaluating Methotrexate or Leflunomide + Targeted Therapy Versus Methotrexate or Leflunomide + Sulfasalazine + Hydroxychloroquine in Patients With Rheumatoid Arthritis and Insufficient Response to Methotrexate or Leflunomide
Lead sponsor
University Hospital, Strasbourg, France
Phase
Phase 4
Overall status
Recruiting
Start date
March 30, 2016
Completion date
March 31, 2029
Enrollment
286 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

insufficient response to methotrexate or leflunomide, rheumatoid arthritis